Marker therapeutics announces upcoming presentations on mt-601 in relapsed non-hodgkin and hodgkin lymphoma at the 67th ash annual meeting

Ongoing phase 1 apollo study investigating mt-601 in patients with relapsed b cell lymphomas showed encouraging preliminary efficacy data

ASH Ratings Summary

ASH Quant Ranking